Alpha-2 agonists: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "alpha" to "α") |
Elcatracho (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Medications== | ==Medications== | ||
*[[clonidine]] | *[[clonidine]] | ||
*[[dexmedetomidine]] | |||
*[[guanabenz]] | *[[guanabenz]] | ||
*[[guanfacine]] | *[[guanfacine]] | ||
*[[methyldopa]] | *[[methyldopa]] | ||
*[[moxonidine]] | *[[moxonidine]] | ||
*[[Xylazine toxicity|Xylazine]] (veterinary med, drug of abuse) | |||
==Adverse effects== | ==Adverse effects== | ||
Latest revision as of 16:54, 29 November 2020
Background
- Central α agonists lower blood pressure by stimulating α-receptors in the brain which causes peripheral vasodilation
Medications
- clonidine
- dexmedetomidine
- guanabenz
- guanfacine
- methyldopa
- moxonidine
- Xylazine (veterinary med, drug of abuse)
Adverse effects
- sedation
- drying of the nasal mucosa
- rebound hypertension